-
Je něco špatně v tomto záznamu ?
Melanoma treatment: from conventional to nanotechnology
H. Mishra, PK. Mishra, A. Ekielski, M. Jaggi, Z. Iqbal, S. Talegaonkar,
Jazyk angličtina Země Německo
Typ dokumentu časopisecké články, přehledy
NLK
PubMed Central
od 1979
Medline Complete (EBSCOhost)
od 2003-04-01
ROAD: Directory of Open Access Scholarly Resources
od 1997
- MeSH
- kombinovaná terapie škodlivé účinky metody MeSH
- lidé MeSH
- management nemoci MeSH
- melanom diagnóza etiologie mortalita terapie MeSH
- nádorové biomarkery MeSH
- nanomedicína metody MeSH
- nanotechnologie metody MeSH
- objevování léků MeSH
- standardní péče MeSH
- zvířata MeSH
- Check Tag
- lidé MeSH
- zvířata MeSH
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
INTRODUCTION: Melanoma is the most serious form of skin cancer causing most of the skin cancer-related deaths. The incidence of melanoma has risen so dramatically over past few years that no other solid or blood malignancy comes close to it in terms of increased incidence. The main problem associated with the treatment of melanoma is low response rate to the existing treatment modalities, which in turn is due to the incomplete response by chemotherapeutic agents and inherent resistance of melanoma cells. MATERIALS AND METHODS: Conventional therapeutic strategies, as well as, recent literature on melanoma have been thoroughly studied. This review summarizes the base of anti-melanoma treatment with conventional chemotherapeutic drugs, followed by an account of recent studies which explored the potential of nanotechnology and newer strategies and agents in melanoma treatment. CONCLUSION: Although melanoma is curable if detected in its early localized form, metastatic melanoma continues to be a therapeutic challenge. Metastatic melanoma has a very poor prognosis and conventional therapies have not improved the outcomes of the treatment so far. For this reason, newer combinations of anti-melanoma drugs and newer strategies utilizing nanotechnology have been constantly explored.
Dabur Research Foundation Ghaziabad India
Department of Wood Processing Technologies Mendel University in Brno Brno Czech Republic
School of Pharmaceutical Education and Research Jamia Hamdard New Delhi India
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc19000482
- 003
- CZ-PrNML
- 005
- 20190122093516.0
- 007
- ta
- 008
- 190107s2018 gw f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.1007/s00432-018-2726-1 $2 doi
- 035 __
- $a (PubMed)30094536
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a gw
- 100 1_
- $a Mishra, Harshita $u School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India.
- 245 10
- $a Melanoma treatment: from conventional to nanotechnology / $c H. Mishra, PK. Mishra, A. Ekielski, M. Jaggi, Z. Iqbal, S. Talegaonkar,
- 520 9_
- $a INTRODUCTION: Melanoma is the most serious form of skin cancer causing most of the skin cancer-related deaths. The incidence of melanoma has risen so dramatically over past few years that no other solid or blood malignancy comes close to it in terms of increased incidence. The main problem associated with the treatment of melanoma is low response rate to the existing treatment modalities, which in turn is due to the incomplete response by chemotherapeutic agents and inherent resistance of melanoma cells. MATERIALS AND METHODS: Conventional therapeutic strategies, as well as, recent literature on melanoma have been thoroughly studied. This review summarizes the base of anti-melanoma treatment with conventional chemotherapeutic drugs, followed by an account of recent studies which explored the potential of nanotechnology and newer strategies and agents in melanoma treatment. CONCLUSION: Although melanoma is curable if detected in its early localized form, metastatic melanoma continues to be a therapeutic challenge. Metastatic melanoma has a very poor prognosis and conventional therapies have not improved the outcomes of the treatment so far. For this reason, newer combinations of anti-melanoma drugs and newer strategies utilizing nanotechnology have been constantly explored.
- 650 _2
- $a zvířata $7 D000818
- 650 _2
- $a nádorové biomarkery $7 D014408
- 650 _2
- $a kombinovaná terapie $x škodlivé účinky $x metody $7 D003131
- 650 _2
- $a management nemoci $7 D019468
- 650 _2
- $a objevování léků $7 D055808
- 650 _2
- $a lidé $7 D006801
- 650 _2
- $a melanom $x diagnóza $x etiologie $x mortalita $x terapie $7 D008545
- 650 _2
- $a nanomedicína $x metody $7 D050997
- 650 _2
- $a nanotechnologie $x metody $7 D036103
- 650 _2
- $a standardní péče $7 D059039
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Mishra, Pawan K $u Department of Wood Processing Technologies, Mendel University in Brno, Brno, Czech Republic.
- 700 1_
- $a Ekielski, Adam $u Department of Production Management and Engineering, Faculty of Production Engineering, Warsaw University of Life Sciences, Warsaw, Poland.
- 700 1_
- $a Jaggi, Manu $u Dabur Research Foundation, Ghaziabad, India.
- 700 1_
- $a Iqbal, Zeenat $u School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India.
- 700 1_
- $a Talegaonkar, Sushama $u School of Pharmaceutical Education and Research, Jamia Hamdard, New Delhi, India. stalegaonkar@jamiahamdard.ac.in. Department of Pharmaceutics, Delhi Pharmaceutical Sciences and Research University, Government of NCT of Delhi, New Delhi, India. stalegaonkar@jamiahamdard.ac.in.
- 773 0_
- $w MED00009972 $t Journal of cancer research and clinical oncology $x 1432-1335 $g Roč. 144, č. 12 (2018), s. 2283-2302
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/30094536 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y a $z 0
- 990 __
- $a 20190107 $b ABA008
- 991 __
- $a 20190122093735 $b ABA008
- 999 __
- $a ok $b bmc $g 1364555 $s 1038605
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2018 $b 144 $c 12 $d 2283-2302 $e 20180809 $i 1432-1335 $m Journal of cancer research and clinical oncology $n J Cancer Res Clin Oncol $x MED00009972
- LZP __
- $a Pubmed-20190107